Skip to main content
Top
Published in: Endocrine 1/2023

11-04-2023 | Obesity | Brief report

Persistent severe visual field impairment is associated with obesity and tumour invasiveness, but not with pituitary dysfunction, in patients with craniopharyngioma

Authors: Salvatore Giovinazzo, Giovanni Oliverio, Oana R. Cotta, Ylenia Alessi, Filippo F. Angileri, Felicia Ferreri, Rosaria Certo, Antonio De Maria, Angela Alibrandi, Pasquale Aragona, Salvatore Cannavò, Francesco Ferraù

Published in: Endocrine | Issue 1/2023

Login to get access

Abstract

Purpose

Craniopharyngiomas (CP) are benign tumours of the sellar region. Hypopituitarism, visual deficits, hypothalamic damage with consequent obesity and related increased cardiovascular risk, are complications due to the tumour itself or secondary to treatment strategy. We retrospectively correlated visual field status with clinical, neuroradiological, histopathological features and management strategy, in a single-centre cohort of patients with CP.

Methods

Thirty-four patients (16 M; median age 27.2 ± 21.8 yrs) with CP were included. We evaluated visual field status, assessed by means of standard automated perimetry and expressed as mean deviation (MD), at last follow-up visit (median 14 ± 11.7 yrs). MD has been correlated with clinical, radiological, histological data and treatment modalities.

Results

In univariate analysis worst eye MD was significantly associated with panhypopituitarism (p 0.010). In multivariable linear regression, panhypopituitarism (p 0.008), CP recurrence (p 0.020) and DI (p 0.004) were found to be the main independent predictors of a worse visual field outcome. When stratifying patients according to the degree of visual field impairment (MD < −12 dB Vs MD > −12 dB), the main independent predictors of worse visual field outcome were older age at diagnosis (p 0.010), CP histological subtype (p 0.004), invasiveness (p 0.04), CP recurrence (p 0.035), DI (p 0.002) and weight at last follow-up (p 0.012).

Conclusion

In CP patients the long-term ophthalmological impairment is frequent, especially at older age, and strictly related to tumour invasiveness and recurrence, and associated to pituitary disfunction and obesity.
Literature
2.
go back to reference C. Capatina, M. Vintila, I. Gherlan, A. Dumitraşcu, A. Caragheorgheopol, C. Procopiuc, V. Ciubotaru, C. Poiana, Craniopharyngioma—clinical and therapeutic outcome data in mixed cohort of adult and pediatric cases. Acta Endocrinol. (Buchar). (2018). https://doi.org/10.4183/aeb.2018.549 C. Capatina, M. Vintila, I. Gherlan, A. Dumitraşcu, A. Caragheorgheopol, C. Procopiuc, V. Ciubotaru, C. Poiana, Craniopharyngioma—clinical and therapeutic outcome data in mixed cohort of adult and pediatric cases. Acta Endocrinol. (Buchar). (2018). https://​doi.​org/​10.​4183/​aeb.​2018.​549
5.
go back to reference I. Forchheimer, C.G. de Moraes, C.C. Teng, F. Folgar, C. Tello, R. Ritch, J.M. Liebmann, Baseline mean deviation and rates of visual field change in treated glaucoma patients. Eye Lond. 25, 626–632 (2011)CrossRefPubMedPubMedCentral I. Forchheimer, C.G. de Moraes, C.C. Teng, F. Folgar, C. Tello, R. Ritch, J.M. Liebmann, Baseline mean deviation and rates of visual field change in treated glaucoma patients. Eye Lond. 25, 626–632 (2011)CrossRefPubMedPubMedCentral
6.
go back to reference S. Cannavò, F. Marini, F. Trimarchi, Patients with craniopharyngiomas: therapeutical difficulties with growth hormone. J. Endocrinol. Invest 31, 56–60 (2008)PubMed S. Cannavò, F. Marini, F. Trimarchi, Patients with craniopharyngiomas: therapeutical difficulties with growth hormone. J. Endocrinol. Invest 31, 56–60 (2008)PubMed
8.
go back to reference F. Ferraù, F. Spagnolo, O.R., Cotta, L. Cannavò, A. Alibrandi, G. Russo, T. Aversa, F. Trimarchi, S. Cannavò, Visceral adiposity index as an indicator of cardiometabolic risk in patients treated for craniopharyngioma. Endocrine (2017). https://doi.org/10.1007/s12020-016-1196-y F. Ferraù, F. Spagnolo, O.R., Cotta, L. Cannavò, A. Alibrandi, G. Russo, T. Aversa, F. Trimarchi, S. Cannavò, Visceral adiposity index as an indicator of cardiometabolic risk in patients treated for craniopharyngioma. Endocrine (2017). https://​doi.​org/​10.​1007/​s12020-016-1196-y
10.
go back to reference R.R. Sharma, M.J. Chandy, S.D. Lad, Diencephalic syndrome of emaciation in an adult associated with a suprasellar craniopharyngioma: a case report. Br. J. Neurosurg. 4, 77–80 (1990)CrossRefPubMed R.R. Sharma, M.J. Chandy, S.D. Lad, Diencephalic syndrome of emaciation in an adult associated with a suprasellar craniopharyngioma: a case report. Br. J. Neurosurg. 4, 77–80 (1990)CrossRefPubMed
Metadata
Title
Persistent severe visual field impairment is associated with obesity and tumour invasiveness, but not with pituitary dysfunction, in patients with craniopharyngioma
Authors
Salvatore Giovinazzo
Giovanni Oliverio
Oana R. Cotta
Ylenia Alessi
Filippo F. Angileri
Felicia Ferreri
Rosaria Certo
Antonio De Maria
Angela Alibrandi
Pasquale Aragona
Salvatore Cannavò
Francesco Ferraù
Publication date
11-04-2023
Publisher
Springer US
Published in
Endocrine / Issue 1/2023
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-023-03359-x

Other articles of this Issue 1/2023

Endocrine 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine